{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T23:28:01Z","timestamp":1769815681525,"version":"3.49.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 59-year-old woman with history of metastatic melanoma, currently on nivolumab, presents for a restaging FDG PET\/CT scan. New subcutaneous hypermetabolic foci are seen in bilateral lower extremities, suggestive of recurrent melanoma. She is referred for percutaneous image-guided biopsy for definitive diagnosis of progressive disease. Ultrasound shows the subcutaneous foci to be hyperechoic (fat density), and biopsy of the right thigh nodule shows fat necrosis with no evidence of tumor. Fat necrosis, an immune-related adverse event, can be FDG-avid and mimic malignancy on PET\/CT scan.<\/jats:p>","DOI":"10.1097\/rlu.0000000000002862","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:25:43Z","timestamp":1574900743000},"page":"125-126","source":"Crossref","is-referenced-by-count":13,"title":["Nivolumab-Induced Subcutaneous Fat Necrosis"],"prefix":"10.1097","volume":"45","author":[{"given":"Peeyush","family":"Bhargava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley","family":"Flynt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Marcal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,12,4]]},"reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","year":"2015","journal-title":"N Engl J Med"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00262-018-2229-6","article-title":"Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET-CT","volume":"68","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","year":"2009","journal-title":"Clin Cancer Res"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2018.03.006","article-title":"Detection of immune-related adverse events by medical imaging in patients treated with anti\u2013programmed cell death 1","volume":"96","year":"2018","journal-title":"Eur J Cancer"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40425-016-0162-9","article-title":"Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade","volume":"4","year":"2016","journal-title":"J Immunother Cancer"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1097\/RLU.0000000000001673","article-title":"Ipilimumab-induced organizing pneumonia on 18F-FDG PET\/CT in a patient with malignant melanoma","volume":"42","year":"2017","journal-title":"Clin Nucl Med"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/RLU.0b013e318248549a","article-title":"Ipilimumab-induced colitis on FDG PET\/CT","volume":"37","year":"2012","journal-title":"Clin Nucl Med"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1097\/RLU.0000000000000940","article-title":"Pancreatitis secondary to anti\u2013programmed death receptor 1 immunotherapy diagnosed by FDG PET\/CT","volume":"40","year":"2015","journal-title":"Clin Nucl Med"},{"key":"bib9-20230925","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/RLU.0000000000000606","article-title":"Ipilimumab-induced hepatitis on 18F-FDG PET\/CT in a patient with malignant melanoma","volume":"40","year":"2015","journal-title":"Clin Nucl Med"},{"key":"bib10-20230925","first-page":"e7","article-title":"Subcutaneous fat necrosis due to molecular-targeted therapy","volume":"44","year":"2017","journal-title":"J Dermatol"},{"key":"bib11-20230925","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/archderm.1961.01580080054006","article-title":"Nodular fat necrosis and pancreatic diseases","volume":"83","year":"1961","journal-title":"Arch Dermatol"},{"key":"bib12-20230925","first-page":"E34","article-title":"Panniculitis, pancreatitis, and polyarthritis: a rare clinical syndrome","volume":"101","year":"2018","journal-title":"Cutis"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002862","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:06:26Z","timestamp":1695621986000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002862"}},"subtitle":["Another FDG-Avid Immune-Related Adverse Event"],"short-title":[],"issued":{"date-parts":[[2019,12,4]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002862","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,4]]}}}